Welcome
Support Centre
31 October 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Brixton Early Psychosis Project
ISRCTN ISRCTN73679874
DOI 10.1186/ISRCTN73679874
ClinicalTrials.gov identifier
EudraCT number
Public title Brixton Early Psychosis Project
Scientific title
Acronym N/A
Serial number at source RDC01657
Study hypothesis The objective is to investigate whether patients randomly allocated to the Early Psychosis Service have better social and clinical outcomes than those managed by standard community teams. The primary outcomes are relapse, readmission and detention. Secondary outcomes of interest will include clinical and social functioning, user and carer satisfaction and burden. The research will also assess fidelity to the ACT model and describe team and services processes, training and any adaptations of the model needed to target early psychosis.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Schizophrenia and other psychoses
Participants - inclusion criteria 1. Aged 16 - 35 years
2. Living in the catchment areas served by the team (pop. approx 150,000)
3. Presenting with a first or second episode of a psychotic disorder (International Statistical Classification of Diseases and Related Health Problems, tenth edition [ICD-10] schizophrenia spectrum disorder including unspecified non-organic psychosis)

Every effort will be made to include as many eligible patients as possible. For example, assistance of interpreters associated with the clinical service will be enlisted in order to include patients whose first language is not English..
Participants - exclusion criteria Patients with primary substance use disorder will not be eligible for the study.
Anticipated start date 01/01/2000
Anticipated end date 01/07/2003
Status of trial Completed
Patient information material
Target number of participants 144
Interventions 1. Experimental group: will receive care from the Early Psychosis Service (a multi professional Assertive Community Treatment team targeted at people suffering their first or second episode of psychotic illness
2. Control group: will receive standard care as currently delivered though existing Sector Teams for the catchment areas
Primary outcome measure(s) Relapse, readmission and detention at 18 months. We define relapse as any case noted record of a change in clinical state that has resulted in an increase in psychotrophic medication and/or an admission to hospital.
Secondary outcome measure(s) Secondary outcome measures will include a range of clinical social and service use outcomes:
1. Clinical measures at all three time points:
1.1. Brief psychiatric rating scale (BPRS)
1.2. Positive and negative syndrome scale (PANSS)
1.3. Global Assessment of Functioning (GAF) scale
1.4. Calgary Depression Scale
1.5. Insight Scale
1.6. Treatment compliance at 6 and 18 months
2. Social functioning at all three time points:
2.1. Employment status
2.2. Housing status
2.3. Benefit uptake
2.4. Social network scale
2.5. Life Skills Profile (LSP)
3. Patient and carer satisfaction/burden:
3.1. Verona satisfaction scale
3.2. Family burden at 18 months
4. Service use and costs: assessed retrospectively at 18 months based on a combination of service records and a standard instrument - the Client Service Receipt Inventory. Resource use will be identified for both treatment and control group and will include:
4.1. Medication costs
4.2. NHS services
4.3. Local authority services accommodation
4.4. Contact with criminal justice and all other services
4.5. Indirect economic impacts (particularly lost employment and caregiver burden) will also be included.
5. Team process measures and fidelity - team activity logs e.g.:
5.1. Contacts per client
5.2. Out of hours contacts
5.3. Interventions offered
5.4. Adherence to ACT model
Sources of funding NHS Executive London (UK)
Trial website
Publications 1. 2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15485934
2. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20435962
Contact name Prof  Thomas  Craig
  Address Kings College London
4th Floor
North Wing
St Thomas Hospital
Lambeth Palace Road
  City/town London
  Zip/Postcode SE1 7EH
  Country United Kingdom
  Tel +44 (0)20 7928 9292/3771
  Email t.craig@iop.kcl.ac.uk
Sponsor NHS R&D Regional Programme Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0) 20 7307 2622
  Fax +44 (0) 20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 23/01/2004
Last edited 04/05/2010
Date ISRCTN assigned 23/01/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.